These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 14965223)

  • 21. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
    Guardiola E; Delroeux D; Heyd B; Combe M; Lorgis V; Demarchi M; Stein U; Royer B; Chauffert B; Pivot X
    World J Surg Oncol; 2009 Feb; 7():14. PubMed ID: 19203351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete remission of ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis treated by paclitaxel and carboplatin chemotherapy: a case report.
    Tohya T; Shimajiri S; Onoda C; Yoshimura T
    Int J Gynecol Cancer; 2004; 14(2):378-80. PubMed ID: 15086742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary.
    Balat O
    Eur J Gynaecol Oncol; 2004; 25(2):195-6. PubMed ID: 15032280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of ovarian cancer stage IV and advanced rectal cancer responding to paclitaxel/carboplatin].
    Kawaguchi R; Furukawa N; Morimoto Y; Ohi M; Osawa T; Koike H; Miyake T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):619-22. PubMed ID: 15114712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
    Sharma R; Graham J; Blagden S; Gabra H
    BMC Cancer; 2011 Jul; 11():289. PubMed ID: 21745358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
    Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer.
    Hempling RE; Piver MS; Natarajan N; Baker TR; Thompson JM; Hicks ML; Mettlin CJ
    J Surg Oncol; 1993 Sep; 54(1):38-44. PubMed ID: 8377503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Selecting postoperative chemotherapy regimen and optimizing therapy cycle for stage II-IV ovarian epithelial carcinoma].
    Huang YW; Li YJ; Li MD
    Ai Zheng; 2005 Aug; 24(8):994-7. PubMed ID: 16086880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
    Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
    Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
    Samaritani R; Corrado G; Vizza E; Sbiroli C
    BMC Cancer; 2007 Apr; 7():65. PubMed ID: 17433113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
    Baker TR; Piver MS; Hempling RE
    Cancer; 1994 Jul; 74(2):656-63. PubMed ID: 8033045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
    Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
    Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
    Vapattanawong P
    J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
    Kawashima T; Murakami H; Kanamori T; Nakamura Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):461-3. PubMed ID: 17353644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer.
    Méndez LE; Mueller A; Salom E; González-Quintero VH
    Obstet Gynecol; 2003 Nov; 102(5 Pt 2):1200-2. PubMed ID: 14607056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
    Bakkum-Gamez JN; Richardson DL; Seamon LG; Aletti GD; Powless CA; Keeney GL; O'Malley DM; Cliby WA
    Int J Gynecol Cancer; 2010 Oct; 20(7):1125-31. PubMed ID: 21495213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.